Our Differentiation 

Our major innovation is that our products not only address specific conditions, but also risk factors for these conditions. Therefore, the products play an important role in prevention.

ESPA's products are characterized by:

​

• targeting the biochemical sites of disease origin and not only symptoms.

• combining systemic approach and topical management.

• managing the increased risk of comorbidities accompanying psoriasis such as diabetes, cardiovascular and cardiometabolic diseases and arthritis. 

• clinically evaluated.

• high efficacy and well-established safety profile supported by preclinical and clinical research.

• easy accessibility as “OTC” products.

​